Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Ad26 Mos4 HIV (Primary) ; Aluminium phosphate; HIV clade C gp140 vaccine
- Indications HIV-1 infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms Imbokodo
- Sponsors Janssen Vaccines and Prevention B.V
- 02 Aug 2022 Results of an immune correlates analysis presented at the 24th International AIDS Conference
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 18 Jan 2022 Planned End Date changed from 23 Jul 2022 to 28 Feb 2022.